title: Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia.
abstract: BACKGROUND
  To enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial.
  
  
  METHODS
  Using a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance.
  
  
  RESULTS
  After eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or ziprasidone (n=18; mean 88.9 mg) treatment had not improved further.
  
  
  CONCLUSIONS
  The findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly.
authors.affiliation: CWZ General Hospital Nijmegen, Dept. of Psychiatry, Postbus 9015, 6500 GS Nijmegen, The Netherlands. k.grootens@cwz.nl
authors.forename: K P
authors.initials: KP
authors.lastname: Grootens
authors.forename: N M J
authors.initials: NM
authors.lastname: van Veelen
authors.forename: M M
authors.initials: MM
authors.lastname: Sitskoorn
authors.forename: B G C
authors.initials: BG
authors.lastname: Sabbe
authors.forename: J
authors.initials: J
authors.lastname: Peuskens
authors.forename: J K
authors.initials: JK
authors.lastname: Buitelaar
authors.forename: R J
authors.initials: RJ
authors.lastname: Verkes
authors.forename: R S
authors.initials: RS
authors.lastname: Kahn
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001569:Benzodiazepines / Q000008:administration & dosage*; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D057915:Drug Substitution / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D000077152:Olanzapine; D010879:Piperazines / Q000008:administration & dosage*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; C092292:ziprasidone; D000077152:Olanzapine